Financial Services - Germany



Buy (old: Hold) 27.05.2024

EUR 1.20 (old: EUR 1.30)

EGM approved merger with CAPEX chg est. & PT

Topic: During the recently held extraordinary general meeting, NAGA received the approval for the merger with CAPEX with a 99.81% majority. As the pending regulatory change of control process is rather a formality, we adjust our estimates, now fully reflecting the merger with CAPEX. For FY24 we now expect:

- Sales of € 77.8m, resulting from 15.9m transactions (eNuW) and an avg. revenue per trade of € 4.9 (eNuw). Apart from the technical impact of the merger, the stronger trading figures from peers that indicate an upswing of customer activity in the market, paired with cross-selling potentials between NAGA and CAPEX, are driving sales. The number of active customers (eNuW: 46k) and trading volumes (eNuW: € 340bn; € 21.4k per trade) should develop accordingly.
- EBITDA is expected to come in at a solid € 10.1m, thanks to the strong topline development as well as anticipated synergy effects. While management expects an OPEX reduction of some € 10m, we are a bit more conservative, anticipating only € 8.5m (eNuW: marketing spending: € 4m, personnel expenses: € 2.5m, other operating expenses € 2m). EBT is seen at negative € 0.7m.

Despite the fact, that the merger looks like an unfavourable deal for existing shareholder due to its dilutive nature(existing shareholders possess only 25% of all outstanding shares post merger and the outstanding convertible bond as well as management's long-term incentive scheme could dilute them further), the growth potential of the joint Group is huge: In 2026, management plans to generate USD 250m in sales with 40% EBITDA margins. While we think this is a rather optimistic scenario, the past has already shown that an incremental positive change in the sentiment could have an enormous effect on the P&L of NAGA. The leverage of the joint Group could even scale this effect. Still, in our base case scenario we conservatively only anticipating € 98m in sales and an EBITDA € 20m (20% EBITDA margin), leaving room for positive surprises.

In light of the revitalization of customer activity in the brokerage space, paired with cross-selling and synergy effects arising from the merger, we see significant growth potential again.

BUY with a new PT of € 1.20 (old: € 1.30), based on DCF.

Y/E 31.12 (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	24.4	52.9	57.6	45.5	77.8	89.0
Sales growth	291.3%	117.1%	8.9%	-21.0%	71.0%	14.4%
EBITDA	4.5	-4.2	-13.7	7.0	10.1	15.4
Net debt (if net cash=0)	-4.0	-7.6	-2.7	-0.4	-5.0	-4.5
FCF	-3.6	-27.3	-32.6	-4.6	-3.1	-0.5
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0
EPS pro forma	-0.01	-0.20	-0.69	-0.05	-0.00	0.02
EBITDA margin	18.5%	-7.9%	-23.8%	15.3%	13.0%	17.3%
ROCE	0.8%	-7.0%	-29.8%	0.4%	1.4%	3.6%
EV/sales	1.4	0.7	0.7	0.9	2.2	1.9
EV/EBITDA	7.6	-8.2	-2.9	6.0	17.0	11.1
PER	-55.3	-3.9	-1.1	-17.3	-256.3	51.0
Adjusted FCF yield	0.2%	-24.5%	-93.4%	1.5%	1.8%	4.5%

Source: Company data, NuWays, Close price as of 23.05.2024



warket data	
Share price (in €)	0.78
Market cap (in € m)	176.7
Number of shares (in m pcs)	226.5
Enterprise value (in € m)	171.7
Ø trading volume (6 months)	27

Mouleat date


	laentifier
Bloomberg	N4G GR
Reuters	N4G
WKN	A161NR
ISIN	DE000A161NR7


Key shareholders				
Fosun Fintech Holdings	33.9%			
Apeiron	12.3%			
Management	12.2%			
Other	43.2%			


Estimates changes						
	<u>2023e</u>	<u>2024e</u>	<u>2025e</u>			
Sales	0%	86%	94%			
EBIT	0%	211%	285%			
EPS	0%	84%	492%			

Comment on changes

 Fully reflecting the pro forma estimates of the joint Group (NAGA+CAPEX from FY24 onwards







Company description

The NAGA Group AG is a financial technology and services company that develops and markets disruptive online brokerage applications. The company's proprietary platform offers a range of products, from stock trading to investing and cryptocurrencies to a physical VISA debit card.

Guidance

Update - 27.05.2024



Financials

Profit and loss (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	24.4	52.9	57.6	45.5	77.8	89.0
Sales growth	291.3%	117.1%	8.9%	-21.0%	71.0%	14.4%
Cost of sales	3.5	8.5	15.0	18.2	23.3	25.4
Gross profit	20.9	44.4	42.6	27.3	54.5	63.7
Sales and marketing	8.7	32.5	28.3	5.9	21.8	23.7
General and administration	4.1	8.0	10.7	7.9	12.8	14.0
Research and development	2.5	3.5	6.7	5.2	5.8	6.3
Other operating income	3.5	3.8	6.1	4.6	6.2	6.8
Other operating expenses	4.5	8.5	16.7	5.9	10.1	11.0
Total operating expenses	16.4	48.6	56.3	20.3	44.4	48.2
Unusual or infrequent items	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	4.5	-4.2	-13.7	7.0	10.1	15.4
Depreciation	3.4	5.3	23.1	6.4	7.0	7.6
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.2	0.0	0.0	0.0	0.0	0.0
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	0.9	-9.5	-36.9	0.6	3.1	7.8
Interest income	0.0	0.0	0.1	0.0	0.1	0.1
Interest expenses	0.7	1.7	0.4	3.1	3.9	4.5
Investment income	0.0	0.0	0.0	0.0	0.0	0.0
Financial result	-0.7	-1.7	-0.3	-3.1	-3.8	-4.4
Recurring pretax income from continuing operations	0.3	-11.2	-37.2	-2.4	-0.7	3.5
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	0.3	-11.2	-37.2	-2.4	-0.7	3.5
Income tax expense	0.1 0.2	-0.5 -10.8	-0.1 -37.0	0.0 -2.4	0.0 -0.7	0.0 3.5
Net income from continuing operations Income from discontinued operations (net of tax)	0.2	0.0	-37. 0 0.0	- 2.4 0.0	- 0.7 0.0	0.0
Net income	0.0	-10.8	-37.0	-2.4	- 0.7	3.5
Minority interest	0.8	-10.8	-0.0	-0.0	-0.0	-0.0
Net profit (reported)	- 0.6	-10.1	-37.0	-0.0 -2.4	-0.7	3.5
Average number of shares	42.0	44.2	54.0	54.0	226.5	226.5
EPS reported	-0.01	-0.23	-0.69	-0.05	-0.00	0.02
,						
	2020	2021	2022	2023e	2024e	2025e
Profit and loss (common size) Sales	2020 100.0%	2021 100.0%	100.0%	100.0%	100.0%	100.0%
Profit and loss (common size) Sales Cost of sales	2020 100.0% 14.3%	2021 100.0% 16.0%	100.0% 26.1%	100.0% 40.0%	100.0% 30.0%	100.0% 28.5%
Profit and loss (common size) Sales Cost of sales Gross profit	2020 100.0% 14.3% 85.7%	2021 100.0% 16.0% 84.0%	100.0% 26.1% 73.9%	100.0% 40.0% 60.0%	100.0% 30.0% 70.0%	100.0% 28.5% 71.5%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing	2020 100.0% 14.3% 85.7% 35.7%	2021 100.0% 16.0% 84.0% 61.4%	100.0% 26.1% 73.9% 49.2%	100.0% 40.0% 60.0% 13.0%	100.0% 30.0% 70.0% 28.0%	100.0% 28.5% 71.5% 26.6%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration	2020 100.0% 14.3% 85.7% 35.7% 16.9%	2021 100.0% 16.0% 84.0% 61.4% 15.1%	100.0% 26.1% 73.9% 49.2% 18.6%	100.0% 40.0% 60.0% 13.0% 17.4%	100.0% 30.0% 70.0% 28.0% 16.5%	100.0% 28.5% 71.5% 26.6% 15.7%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1% 13.0%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1% 13.0% 44.7%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0%	100.0% 40.0% 60.0% 13.0% 17.4% 10.1% 13.0% 44.7% 0.0%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8%	100.0% 40.0% 60.0% 13.0% 17.4% 10.1% 13.0% 44.7% 0.0% 15.3%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2%	100.0% 40.0% 60.0% 13.0% 17.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 13.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0%	100.0% 40.0% 60.0% 13.0% 17.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 13.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0%	100.0% 40.0% 60.0% 13.0% 17.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 13.0% 9.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% 0.0%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% 0.0%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 13.0% 9.0% 0.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net)	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% -64.0%	100.0% 40.0% 60.0% 13.0% 17.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 1.4%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 0.0% 0.0% 4.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 8.8%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9% 0.1%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1% 0.0%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% -64.0% 0.1%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 0.0% 0.1%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 0.0% 0.0% 4.0% 0.1%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 0.0% 8.8% 0.1%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9% 0.1% 2.8%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1% 0.0% 3.2%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% -64.0% 0.1% 0.7%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 0.0% 6.8%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 0.0% 0.0% 0.0% 0.0% 4.0% 5.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 8.8% 0.1% 5.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9% 0.1% 2.8% 0.0%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1% 0.0% 3.2% 0.0%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% 0.0% -64.0% 0.1% 0.7% 0.0%	100.0% 40.0% 60.0% 13.0% 17.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 0.1% 6.8% 0.0%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 4.0% 0.1% 5.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 0.0% 5.0% 0.1% 5.0% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9% 0.1% 2.8% 0.0% neg.	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1% 0.0% 3.2% 0.0% neg.	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% 0.0% -64.0% 0.1% 0.7% 0.0% neg.	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% neg.	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% neg.
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9% 0.1% 2.8% 0.0% neg. 1.2%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1% 0.0% 3.2% 0.0% neg21.2%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% 0.0% 0.0% -64.0% 0.1% 0.7% 0.0% neg64.5%	100.0% 40.0% 60.0% 13.0% 17.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 0.0% 0.0% 3.8% 0.0% 0.0% 17.3%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9% 0.1% 2.8% 0.0% neg. 1.2% 0.0%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1% 0.0% 3.2% 0.0% neg21.2% 0.0%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% 0.0% 0.0% -64.0% 0.1% 0.7% 0.0% neg64.5% 0.0%	100.0% 40.0% 60.0% 13.0% 17.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 0.0% 0.1% 6.8% 0.0% neg5.4% 0.0%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 4.0% 0.1% 5.0% 0.0% neg0.9% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 0.0% 0.1% 5.0% 0.0% neg. 3.9% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9% 0.1% 2.8% 0.0% neg. 1.2%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1% 0.0% 3.2% 0.0% neg21.2%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% 0.0% -64.0% 0.1% 0.7% 0.0% neg64.5%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 0.0% 0.1% 6.8% 0.0% neg5.4%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 0.0% 0.0% 3.9%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9% 0.1% 2.8% 0.0% neg. 1.2% 0.0% 1.2% 39.6%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1% 0.0% 3.2% 0.0% neg21.2% 4.1%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% 0.0% -64.0% 0.1% 0.7% 0.0% neg64.5% 0.0%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 0.0% 0.1% 6.8% 0.0% neg5.4% 0.0%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 0.0% 0.0% 3.9% 0.0% 3.9%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9% 0.1% 2.8% 0.0% neg. 1.2% 0.0% 1.2% 39.6% 0.7%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1% 0.0% 3.2% 0.0% neg21.2% 4.1% -20.3%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% 0.0% -64.0% 0.1% 0.7% 0.0% neg64.5% 0.0% -64.5% 0.0% -64.3%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 0.0% 0.1% 6.8% 0.0% neg5.4% 0.0% -5.4%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9% 0.1% 2.8% 0.0% neg. 1.2% 0.0% 1.2% 39.6% 0.7%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1% 0.0% 3.2% 0.0% neg21.2% 4.1% -20.3% -20.3%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% 0.0% -64.0% 0.1% 0.7% 0.0% neg64.5% 0.0% -64.5% 0.0% -64.3%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 0.1% 6.8% 0.0% neg5.4% 0.0% -5.4%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations	2020 100.0% 14.3% 85.7% 35.7% 16.9% 10.3% 14.2% 18.5% 67.3% 0.0% 18.5% 13.8% 0.0% 0.8% 0.0% 3.9% 0.1% 2.8% 0.0% neg. 1.2% 0.0% 1.2% 39.6% 0.7%	2021 100.0% 16.0% 84.0% 61.4% 15.1% 6.6% 7.1% 16.0% 92.0% 0.0% -7.9% 10.1% 0.0% 0.0% -18.1% 0.0% 3.2% 0.0% neg21.2% 4.1% -20.3%	100.0% 26.1% 73.9% 49.2% 18.6% 11.6% 10.7% 29.0% 97.8% 0.0% -23.8% 40.2% 0.0% 0.0% 0.0% -64.0% 0.1% 0.7% 0.0% neg64.5% 0.0% -64.5% 0.0% -64.3%	100.0% 40.0% 60.0% 13.0% 17.4% 11.4% 10.1% 13.0% 44.7% 0.0% 15.3% 14.0% 0.0% 0.0% 0.0% 0.1% 6.8% 0.0% neg5.4% 0.0% -5.4%	100.0% 30.0% 70.0% 28.0% 16.5% 7.5% 8.0% 13.0% 57.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%	100.0% 28.5% 71.5% 26.6% 15.7% 7.1% 7.6% 12.3% 54.2% 0.0% 17.3% 8.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0

Source: Company data, NuWays

Update - 27.05.2024



20 0.4 0.6 0.1 1.1 0.0 1.5 9.5 5.2 0.6 0.0 6.9 5.9 5.6 0.9 1.2 1.0 0.0 3.2	2021 119.6 0.6 0.2 120.3 0.0 1.6 46.8 8.6 0.0 0.0 57.0 177.4 164.1 -1.0 0.0 0.4 1.0 4.2	2022 114.2 0.6 0.2 115.0 0.0 0.2 28.6 3.1 0.0 0.0 31.9 146.9 127.1 -1.0 0.0 2.1 0.4 3.2	2023e 114.2 0.6 0.2 115.0 0.0 0.1 25.8 5.7 0.0 0.0 31.6 146.6 -1.0 0.0 2.1 5.3	2024e 277.5 1.1 0.2 278.8 0.0 5.5 23.2 11.5 1.7 0.0 42.0 320.7 296.5 -1.0 0.0 2.1 6.5	2025e 277.5 1.1 0.2 278.8 0.0 6.3 25.5 11.1 1.7 0.0 44.6 323.4 299.9 -1.0 0.0 2.1
0.6 0.1 1.1 0.0 1.5 9.5 5.2 0.6 0.0 6.9 3.0 5.9 5.6 0.9 1.2 1.0 0.0 3.2	0.6 0.2 120.3 0.0 1.6 46.8 8.6 0.0 0.0 57.0 177.4 164.1 -1.0 0.0 0.4 1.0 4.2	0.6 0.2 115.0 0.0 0.2 28.6 3.1 0.0 0.0 31.9 146.9 127.1 -1.0 0.0 2.1 0.4	0.6 0.2 115.0 0.0 0.1 25.8 5.7 0.0 0.0 31.6 146.6 -1.0 0.0 2.1 5.3	1.1 0.2 278.8 0.0 5.5 23.2 11.5 1.7 0.0 42.0 320.7 296.5 -1.0 0.0 2.1	1.1 0.2 278.8 0.0 6.3 25.5 11.1 1.7 0.0 44.6 323.4 299.9 -1.0 0.0
0.1 1.1 0.0 1.5 9.5 5.2 0.6 0.0 6.9 3.0 5.9 5.9 1.2 1.0 0.0 3.2	0.2 120.3 0.0 1.6 46.8 8.6 0.0 0.0 57.0 177.4 164.1 -1.0 0.0 0.4 1.0 4.2	0.2 115.0 0.0 0.2 28.6 3.1 0.0 0.0 31.9 146.9 127.1 -1.0 0.0 2.1 0.4	0.2 115.0 0.0 0.1 25.8 5.7 0.0 0.0 31.6 146.6 124.6 -1.0 0.0 2.1 5.3	0.2 278.8 0.0 5.5 23.2 11.5 1.7 0.0 42.0 320.7 296.5 -1.0 0.0 2.1	0.2 278.8 0.0 6.3 25.5 11.1 1.7 0.0 44.6 323.4 299.9 -1.0 0.0
1.1 0.0 1.5 9.5 5.2 0.6 0.0 6.9 3.0 5.9 5.6 0.9 1.2 1.0 0.0 3.2	120.3 0.0 1.6 46.8 8.6 0.0 0.0 57.0 177.4 164.1 -1.0 0.0 0.4 1.0 4.2	115.0 0.0 0.2 28.6 3.1 0.0 0.0 31.9 146.9 127.1 -1.0 0.0 2.1 0.4	115.0 0.0 0.1 25.8 5.7 0.0 0.0 31.6 146.6 -1.0 0.0 2.1 5.3	278.8 0.0 5.5 23.2 11.5 1.7 0.0 42.0 320.7 296.5 -1.0 0.0 2.1	278.8 0.0 6.3 25.5 11.1 1.7 0.0 44.6 323.4 299.9 -1.0 0.0
0.0 1.5 9.5 5.2 0.6 0.0 6.9 3.0 5.9 5.6 0.9 1.2 1.0	0.0 1.6 46.8 8.6 0.0 0.0 57.0 177.4 164.1 -1.0 0.0 0.4 1.0 4.2	0.0 0.2 28.6 3.1 0.0 0.0 31.9 146.9 127.1 -1.0 0.0 2.1 0.4	0.0 0.1 25.8 5.7 0.0 0.0 31.6 146.6 -1.0 0.0 2.1 5.3	0.0 5.5 23.2 11.5 1.7 0.0 42.0 320.7 296.5 -1.0 0.0 2.1	0.0 6.3 25.5 11.1 1.7 0.0 44.6 323.4 299.9 -1.0
1.5 9.5 5.2 0.6 0.0 6.9 3.0 5.9 5.6 0.9 1.2 1.0 0.0 3.2	1.6 46.8 8.6 0.0 0.0 57.0 177.4 164.1 -1.0 0.0 0.4 1.0 4.2	0.2 28.6 3.1 0.0 0.0 31.9 146.9 127.1 -1.0 0.0 2.1 0.4	0.1 25.8 5.7 0.0 0.0 31.6 146.6 -1.0 0.0 2.1 5.3	5.5 23.2 11.5 1.7 0.0 42.0 320.7 296.5 -1.0 0.0 2.1	6.3 25.5 11.1 1.7 0.0 44.6 323.4 299.9 -1.0
9.5 5.2 0.6 0.0 6.9 5.9 5.6 0.9 1.2 1.0	46.8 8.6 0.0 0.0 57.0 177.4 164.1 -1.0 0.0 0.4 1.0 4.2	28.6 3.1 0.0 0.0 31.9 146.9 127.1 -1.0 0.0 2.1 0.4	25.8 5.7 0.0 0.0 31.6 146.6 -1.0 0.0 2.1 5.3	23.2 11.5 1.7 0.0 42.0 320.7 296.5 -1.0 0.0 2.1	25.5 11.1 1.7 0.0 44.6 323.4 299.9 -1.0 0.0
5.2 0.6 0.0 6.9 5.9 5.6 0.9 1.2 1.0 0.0	8.6 0.0 0.0 57.0 177.4 164.1 -1.0 0.0 0.4 1.0 4.2	3.1 0.0 0.0 31.9 146.9 127.1 -1.0 0.0 2.1 0.4	5.7 0.0 0.0 31.6 146.6 -1.0 0.0 2.1 5.3	11.5 1.7 0.0 42.0 320.7 296.5 -1.0 0.0 2.1	11.1 1.7 0.0 44.6 323.4 299.9 -1.0 0.0
0.6 0.0 6.9 3.0 5.9 5.6 0.9 1.2 1.0 0.0	0.0 0.0 57.0 177.4 164.1 -1.0 0.0 0.4 1.0 4.2	0.0 0.0 31.9 146.9 127.1 -1.0 0.0 2.1 0.4	0.0 0.0 31.6 146.6 124.6 -1.0 0.0 2.1 5.3	1.7 0.0 42.0 320.7 296.5 -1.0 0.0 2.1	1.7 0.0 44.6 323.4 299.9 -1.0 0.0
5.9 5.9 5.6 5.9 1.2 1.0 5.0	0.0 57.0 177.4 164.1 -1.0 0.0 0.4 1.0 4.2	0.0 31.9 146.9 127.1 -1.0 0.0 2.1 0.4	0.0 31.6 146.6 124.6 -1.0 0.0 2.1 5.3	0.0 42.0 320.7 296.5 -1.0 0.0 2.1	0.0 44.6 323.4 299.9 -1.0 0.0
5.9 5.9 5.6 0.9 1.2 1.0 0.0 3.2	57.0 177.4 164.1 -1.0 0.0 0.4 1.0 4.2	31.9 146.9 127.1 -1.0 0.0 2.1 0.4	31.6 146.6 124.6 -1.0 0.0 2.1 5.3	42.0 320.7 296.5 -1.0 0.0 2.1	44.6 323.4 299.9 -1.0 0.0
5.9 5.6 0.9 1.2 1.0 0.0 3.2	177.4 164.1 -1.0 0.0 0.4 1.0 4.2	146.9 127.1 -1.0 0.0 2.1 0.4	146.6 124.6 -1.0 0.0 2.1 5.3	296.5 -1.0 0.0 2.1	323.4 299.9 -1.0 0.0
5.9 5.6 0.9 1.2 1.0 0.0	-1.0 0.0 0.4 1.0 4.2	-1.0 0.0 2.1 0.4	-1.0 0.0 2.1 5.3	-1.0 0.0 2.1	-1.0 0.0
5.9 5.6 0.9 1.2 1.0 0.0	-1.0 0.0 0.4 1.0 4.2	-1.0 0.0 2.1 0.4	-1.0 0.0 2.1 5.3	-1.0 0.0 2.1	-1.0 0.0
5.6 0.9 1.2 1.0 0.0 3.2	0.0 0.4 1.0 4.2	0.0 2.1 0.4	0.0 2.1 5.3	0.0 2.1	0.0
0.9 1.2 1.0 0.0 3.2	0.4 1.0 4.2	2.1 0.4	2.1 5.3	2.1	
1.2 1.0 0.0 3.2	1.0 4.2	0.4	5.3		∠. ۱
1.0 0.0 3.2	4.2				6.5
0.0 3.2		J.Z	2.0	4.5	4.9
3.2		0.0	0.0	0.0	0.0
	0.0 8.4	15.1	13.6	12.2	11.0
١ ٨					0.0
					0.0
					15.9
					323.4
	2021	2022	2023e	2024e	2025e
					85.8%
					0.3%
					0.1%
					86.2%
					0.0%
					2.0%
					7.9%
					3.4%
					0.5%
					0.0%
					13.8%
1%	100.0%	100.0%	100.0%	100.0%	100.0%
	92.5%	86.5%	85.0%	92.4%	92.7%
ì %	-0.6%	-0.7%	-0.7%	-0.3%	-0.3%
3%	0.0%	0.0%	0.0%	0.0%	0.0%
′%	0.2%	1.4%	1.4%	0.6%	0.6%
) %	0.6%	0.3%	3.6%	2.0%	2.0%
3%	2.4%	2.2%	1.4%	1.4%	1.5%
)%	0.0%	0.0%	0.0%	0.0%	0.0%
1 %	4.7%	10.3%	9.3%	3.8%	3.4%
)%	0.0%	0.0%	0.0%	0.0%	0.0%
)%	0.0%	0.0%	0.0%	0.0%	0.0%
	7.1%	12.5%	10.6%	5.2%	4.9%
)%	100.0%	100.0%	100.0%	100.0%	100.0%
	20 33% 44% 11% 38% 10% 22% 44% 10% 22% 33% 44% 10% 20% 33% 44% 10% 20% 34% 10% 20% 20% 30% 20% 30% 20% 30% 20% 30% 20% 30% 20% 30% 20% 30% 20% 30% 20% 30% 30% 30% 30% 30% 30% 30% 3	0.0 0.0 9.2 12.6 8.0 177.4 120 2021 3% 67.4% 4% 0.3% 1% 0.1% 3% 67.8% 0% 0.0% 2% 0.9% 4% 26.4% 1% 4.8% 5% 0.0% 0.0% 2% 32.2% 100.0% 5% 92.5% 6% -0.6% 6% -0.6% 63% 0.0% 7% 0.2% 9% 0.6% 63% 2.4% 0% 0.0% 1% 0	0.0 0.0 0.0 9.2 12.6 18.3 8.0 177.4 146.9 120 2021 2022 3% 67.4% 77.8% 4% 0.3% 0.4% 1% 0.1% 0.1% 3% 67.8% 78.3% 0% 0.0% 0.0% 2% 0.9% 0.1% 4% 26.4% 19.5% 1% 4.8% 2.1% 5% 0.0% 0.0% 0% 0.0% 0.0% 0% 0.0% 100.0% 5% 92.5% 86.5% 3% 0.0% 0.0% 3% 0.0% 0.0% 3% 0.0% 0.0% 3% 0.0% 0.0% 3% 0.0% 0.0% 3% 0.0% 0.0% 3% 0.0% 0.0% 3% 0.0% 0.0% 3% <	0.0 0.0 0.0 0.0 9.2 12.6 18.3 15.6 8.0 177.4 146.9 146.6 120 2021 2022 2023e 3% 67.4% 77.8% 77.9% 4% 0.3% 0.4% 0.4% 1% 0.1% 0.1% 0.1% 3% 67.8% 78.3% 78.4% 0% 0.0% 0.0% 0.0% 2% 0.9% 0.1% 0.1% 4% 26.4% 19.5% 17.6% 4% 26.4% 19.5% 17.6% 1% 4.8% 2.1% 3.9% 5% 0.0% 0.0% 0.0% 0% 0.0% 0.0% 0.0% 2% 32.2% 21.7% 21.6% 3% -0.6% -0.7% -0.7% 3% 0.0% 0.0% 0.0% 3% 0.0% 0.0% 0.0% 3% <td>0.0 0.0 0.0 0.0 9.2 12.6 18.3 15.6 16.7 8.0 177.4 146.9 146.6 320.7 120 2021 2022 2023e 2024e 3% 67.4% 77.8% 77.9% 86.5% 4% 0.3% 0.4% 0.4% 0.3% 1% 0.1% 0.1% 0.1% 0.1% 3% 67.8% 78.3% 78.4% 86.9% 0% 0.0% 0.0% 0.0% 0.0% 2% 0.9% 0.1% 0.1% 1.7% 4% 26.4% 19.5% 17.6% 7.2% 1% 4.8% 2.1% 3.9% 3.6% 5% 0.0% 0.0% 0.0% 0.5% 0% 0.0% 0.0% 0.0% 13.1% 10% 100.0% 100.0% 100.0% 100.0% 2% 32.5% 86.5% 85.0% 92.4%</td>	0.0 0.0 0.0 0.0 9.2 12.6 18.3 15.6 16.7 8.0 177.4 146.9 146.6 320.7 120 2021 2022 2023e 2024e 3% 67.4% 77.8% 77.9% 86.5% 4% 0.3% 0.4% 0.4% 0.3% 1% 0.1% 0.1% 0.1% 0.1% 3% 67.8% 78.3% 78.4% 86.9% 0% 0.0% 0.0% 0.0% 0.0% 2% 0.9% 0.1% 0.1% 1.7% 4% 26.4% 19.5% 17.6% 7.2% 1% 4.8% 2.1% 3.9% 3.6% 5% 0.0% 0.0% 0.0% 0.5% 0% 0.0% 0.0% 0.0% 13.1% 10% 100.0% 100.0% 100.0% 100.0% 2% 32.5% 86.5% 85.0% 92.4%

Source: Company data, NuWays

Update - 27.05.2024



Cash flow statement (EUR m)	2020	2021	2022	2023e	2024e	2025e
Net profit/loss	0.2	-10.8	-37.2	-2.4	-0.7	3.5
Depreciation of fixed assets (incl. leases)	3.4	5.3	23.1	6.4	7.0	7.6
Amortisation of goodwill & intangible assets	0.2	0.0	0.0	0.0	0.0	0.0
Other costs affecting income / expenses	-4.9 -2.0	-10.9 -18.2	-12.2 -37.6	-1.0	0.5 -3.1	-3.5 -0.5
Cash flow from operating activities	-2.0 -0.0	-18.2	-37.6 0.0	-4.6 0.0	-3.1 0.0	-0.5 0.0
Increase/decrease in inventory Increase/decrease in accounts receivable	-0.0 -0.1	-0.5	-0.1	0.0	-5.4	-0.8
	-0.1 2.2	-0.5 2.6	-0.1 5.1	-1.2	-5. 4 2.5	-0.6 0.4
Increase/decrease in accounts payable Increase/decrease in other working capital positions	0.3	2.0 1.7	5.1 5.0	0.0	0.0	0.4
Increase/decrease in working capital positions	2.4	3.8	10.0	-1.2	-2.9	-0.4
Cash flow from operating activities	1.6	-12.9	-14.5	1.7	3.9	7.1
CAPEX	5.1	14.4	18.1	6.4	7.0	7.6
Payments for acquisitions	0.0	0.0	0.0	0.4	0.5	0.0
Financial investments	0.1	27.1	-27.1	-5.0	0.0	0.0
Income from asset disposals	0.1	0.0	0.1	0.0	0.0	0.0
Cash flow from investing activities	-5.2	-41.6	9.2	-1.4	-7.5	-7.6
Cash flow before financing	-3.6	-54.5	-5.4	0.4	-3.6	-0.5
Increase/decrease in debt position	1.9	4.4	-0.1	2.3	1.2	0.0
Purchase of own shares	0.0	-0.6	0.0	0.0	0.0	0.0
Capital measures	4.3	53.6	0.0	0.0	8.2	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others	-0.5	-0.7	-0.0	0.0	0.0	0.0
Effects of exchange rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from financing activities	5.7	57.8	-0.1	2.3	9.4	0.0
Increase/decrease in liquid assets	2.1	3.4	-5.5	2.7	5.8	-0.5
Liquid assets at end of period	5.2	8.6	3.1	5.7	11.5	11.1
Key ratios (EUR m)	2020	2021	2022	2023e	2024e	2025e
P&L growth analysis					=	
Sales growth	291.3%	117.1%	8.9%	-21.0%	71.0%	14.4%
EBITDA growth	1559.4%	-54.2%	-405.3%	-266.0%	-173.7%	121.4%
EBIT growth	-119.5%	-21.6%	-4021.0%	-106.5%	-108.5%	1169.7%
EPS growth	-87.2%	-23.4%	4760.3%	-80.3%	-99.6%	-133.9%
Efficiency	207.0	455.0	440.0	220.2	557.0	700.0
Sales per employee	267.6	455.8	412.9	338.3	557.8	760.9
EBITDA per employee	49.4	-36.2	-98.4	51.9	72.5	132.0
No. employees (average)	91	116	140	134	140	117
Balance sheet analysis	4 60/	1.00/	2.20/	E 00/	1 20/	0.20/
Avg. working capital / sales	4.6%	-1.9%	-2.2%	-5.0%	-1.3%	-0.2%
Inventory turnover (sales/inventory)	0.0 23.0	0.0	0.0 1.2	0.0 1.2	0.0 26.0	0.0
Accounts receivable turnover		10.7 209.3	209.3			26.0 70.0
Accounts payable turnover Cash flow analysis	209.3	209.3	209.3	40.0	70.0	70.0
Free cash flow	-3.6	-27.3	-32.6	-4.6	-3.1	-0.5
Free cash flow/sales	-3.6 -14.6%	-27.3 -51.7%	-56.6%	-4.0 -10.2%	-3.1 -4.0%	-0.5%
FCF / net profit		254.3%	-30.0 % 87.7%	190.6%	-4.0% 450.4%	
Capex / sales	neg. 21.7%	78.6%	-15.7%	3.0%	9.0%	neg. 8.6%
Solvency	21.770	70.070	-13.7 /6	3.0 /0	9.0 /0	0.0 /0
Net debt	-4.0	-7.6	-2.7	-0.4	-5.0	-4.5
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest paid / avg. debt	56.8%	171.3%	47.8%	98.2%	111.6%	75.0%
Returns	00.070	17 1.0 70	17.070	00.270	111.070	7 0.0 70
ROCE	0.8%	-7.0%	-29.8%	0.4%	1.4%	3.6%
ROE	-0.5%	-6.2%	-29.2%	-2.0%	-0.2%	1.2%
Adjusted FCF yield	0.2%	-24.5%	-93.4%	1.5%	1.8%	4.5%
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
DPS	0.0	0.0	0.0	0.0	0.0	0.0
EPS reported	-0.01	-0.23	-0.69	-0.05	-0.00	0.02
Average number of shares	42.0	44.2	54.0	54.0	226.5	226.5
Valuation ratios	72.0	77.4	04.0	0-1.0		220.0
P/BV	0.3	0.2	0.3	0.3	0.6	0.6
EV/sales	1.4	0.7	0.7	0.9	2.2	1.9
			-2.9	6.0	17.0	11.1
EV/EBITDA	7.6	-8.Z	-2.9	0.0	17.0	11.1
EV/EBITDA EV/EBIT	7.6 36.5	-8.2 -3.6	-2.9 -1.1	67.8	55.0	22.0

Update - 27.05.2024



Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
THE NAGA GROUP AG	2

Historical target price and ra	ting changes for THE NA	GA GROUP AG			
Company	Date	Analyst	Rating	Target Price	Close
THE NAGA GROUP AG	16.01.2024	Jarchow, Frederik	Hold	EUR 1.30	EUR 0.81
	17.11.2023	Jarchow, Frederik	Hold	EUR 1.30	EUR 1.13
	16.11.2023	Jarchow, Frederik	Hold	EUR 1.20	EUR 1.13
	18.07.2023	Jarchow, Frederik	Under Review	n.a.	EUR 1.58
	13.07.2023	Jarchow, Frederik	Under Review	EUR 1.60	EUR 1.45

Update - 27.05.2024



1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 27/05/2024 08:02 AM

Date of publication dissemination: 27/05/2024 08:02 AM

Update - 27.05.2024



Contacts

NuWays AG

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow

Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

<u>Instagram</u>



Twitter/X



<u>Linkedlı</u>

